A140410 KR7140410002

Rapport

Cours en clôture Korea Stock Exchange - 05/07/2022
19450.00	KRW		+14.75%

31/05

Mezzion Pharma Co.,Ltd. reçoit une autorisation claire de la FDA pour l'homologation de l'Udenafil pour les maladies cardiaques à ventricule unique

11/05

Mezzion Pharma Co.,Ltd. annonce ses résultats pour le premier trimestre se terminant le 31 mars 2022

23/03

Mezzion Pharma Co.,Ltd. annonce ses résultats pour l'année complète se terminant le 31 décembre 2021

Actualités

Autres langues

Publications officielles

Actualités du secteur

Actualités dans d'autres langues sur MEZZION PHARMA CO.,LTD.

31/05	Mezzion Pharma Co.,Ltd. Receives Clear FDA Path Forward for the Approval of Udenafil fo..
11/05	Mezzion Pharma Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, ..
23/03	Mezzion Pharma Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2..
2021	Mezzion Pharma Announces Positive Data Presented to FDA in Type C Meeting
2021	Mezzion Pharma Co.,Ltd. announced that it has received KRW 20 billion in funding
2021	Mezzion Pharma Co.,Ltd. announced that it expects to receive KRW 20 billion in funding
2021	Mezzion Appoints William Breitenbach as Chief Commercial Officer for Mezzion's Global C..
2021	Mezzion's New Drug Application for Its Orphan Drug Udenafil for the Treatment of Single..
2021	Mezzion Pharma Co. Ltd. Announces Re-Submission of New Drug Application for its Orphan ..
2020	Mezzion Pharma Co. Ltd. Announces Submission of New Drug Application for its Orphan Dru..
2020	Mezzion Pharma's Announces Results from the Pivotal 400-Subject Phase 3 Fuel Trial
2019	Mezzion Pharma Announces the Presentation of the FUEL Trial Data at the American Heart ..
2019	Mezzion Pharma Co.,Ltd. Announces Top Line Data from FUEL Will Be Presented at the Amer..
2019	Mezzion Pharma Co.,Ltd. Announces Positive Results from the Fontan Udenafil Exercise Lo..
2016	Mezzion Pharma Co.,Ltd. announced that it has received KRW 15 billion in funding from a..
2016	Mezzion Pharma Co.,Ltd. announced that it expects to receive KRW 15 billion in funding ..
2016	Mezzion Pharma and NHLBI Initiate Enrollment in a Pivotal Phase 3 Clinical Trial of Ude..
2016	Mezzion Pharma Co. Ltd. Receives Special Protocol Assessment Agreement From FDA For Ude..
2015	Tranche Update on Mezzion Pharma Co.,Ltd.'s Equity Buyback Plan announced on November 1..
2015	Mezzion Pharma Co.,Ltd. authorizes a Buyback Plan.
2015	Mezzion Pharma Co.,Ltd. announces an Equity Buyback for 180,505 shares.
2015	MEZZION PHARMA CO.,LTD.(KOSDAQ : A140410) added to S&P Global BMI Index
2015	Dong-A PharmTech Co. Ltd. cancelled the acquisition of medical equipment sales business..
2015	Mezzion Pharma Co.,Ltd. announced that it has received KRW 42 billion in funding from a..
2015	Mezzion Pharma Co.,Ltd. announced that it expects to receive KRW 42 billion in funding ..
2015	Tranche Update on Mezzion Pharma Co.,Ltd.'s Equity Buyback Plan announced on April 6, 2..
2015	Mezzion Pharma Co.,Ltd.'s Equity Buyback announced on April 6, 2015 has closed with 106..
2015	Mezzion Pharma Co.,Ltd. authorizes a Buyback Plan.
2015	Mezzion Pharma Co.,Ltd. announces an Equity Buyback for 106,007 shares.
2014	Mezzion Pharma Co. Ltd. Appoints Jefferson Gregory to its Board of Directors
2014	Dong-A PharmTech Co. Ltd. agreed to acquire medical equipment sales business of Top Med..
2014	Dong-hyun Park, Chief Executive Officer of Dong-A PharmTech acquired 0.06% stake in Don..
2012	Dong-A PharmTech Co. Ltd. closed an Equity Buyback in the amount of KRW3989.69 mm
2012	Dong-A PharmTech Co. Ltd. announces an Equity Buyback
2012	Dong-A PharmTech Co. Ltd.'s Equity Buyback in the amount of KRW5000 mm has expired
2012	Dong-A PharmTech Co. Ltd.'s Equity Buyback has expired
2012	Dong-A PharmTech Co. Ltd. announces an Equity Buyback
2012	Dong-A PharmTech Co. Ltd. announces an Equity Buyback in the amount of KRW5000 mm

Prochain événement sur MEZZION PHARMA CO.,LTD.

16/08/22

Premier semestre 2022 Publication de résultats (estimation)

Agenda de la société

Evénements à venir dans le secteur

29/07/22	YUHAN CORPORATION : Premier semestre 2022 Publication de résultats (estimation)
04/08/22	KYOWA KIRIN CO., LTD. : Premier semestre 2022 Publication de résultats
04/08/22	MERCK KOMMANDITGESELLSCHAFT AUF AKTIEN : Premier semestre 2022 Publication de résultats
19/08/22	SK BIOPHARMACEUTICALS CO., LTD. : Premier semestre 2022 Publication de résultats (estimation)

Plus d'événements

Secteur

Santé
	Recherche pharmaceutique et médicale
		Produits pharmaceutiques
			Produits pharmaceutiques
				Pharmacies spécialisées et de pointe